Investors
Neola Medical as an investment
Neola Medical’s investment case is based on an urgent global medical need, a patented technology with strong roots in Swedish innovation, and a highly experienced team with deep expertise in MedTech development and commercialization. With a scalable growth potential driven by a global market and recurring revenue model, the company develops Neola® — a class II medical device in clinical phase — designed to set a new standard of care in neonatal lung monitoring. As the company approaches commercial launch, the focus is on securing market authorization in the U.S., followed by Europe.
Growth is supported by a positive investment climate for pediatric medical devices, with global health agendas actively incentivizing innovation for children and newborns. Collaborations with leading neonatal intensive care units in Sweden and the U.S., including participation in the partly FDA-funded Stanford Impact1 program, provide strategic validation and momentum. With a scalable business model based on device sales and recurring revenue from disposables, Neola Medical is well-positioned to advance neonatal care worldwide and create long-term value for its shareholders.
Five Pillars of Shareholder Value
Neola Medical’s long-term shareholder value is built on five important pillars that are worth knowing for current and potential investors:
1. Unmet Clinical Need
Every year, around 15 million babies are born preterm — one in ten worldwide. Respiratory complications are the leading cause of mortality and long-term disability in this group. Neola® addresses a critical gap in neonatal intensive care by aiming to provide real-time insights into lung function where existing methods are limited, invasive, or delayed.
2. Innovative Technology
Neola® is based on the patented GASMAS (Gas in Scattering Media Absorption Spectroscopy) method, developed at the Division of Atomic Physics at Lund University. This innovation enables non-invasive lung monitoring and represents a first-of-its-kind approach to improving neonatal care. The company holds all patent rights for the medical application of the technology.
3. Strong Market Potential
The pediatric medical device segment remains underdeveloped and is experiencing strong growth. Neola® has the potential to establish a new standard of care in a global market with recurring revenue opportunities through single-use disposables.
4. Scalable Business Model
Neola Medical applies a razor-and-blades model: sales of the Neola® device combined with recurring revenue from disposable probe sets. This structure offers scalability, attractive margins, and predictable revenue streams once the product is launched.
5. Proven Team & Network
The company is led by an experienced management team with deep expertise in MedTech commercialization and international market access. Strategic collaborations with leading neonatology experts in Sweden and the U.S., including Children’s Regional Hospital at Cooper in New Jersey and Stanford Impact1, provide strong validation and a solid foundation for U.S. and European market entry.
Presentations
Catch up on Neola Medical’s latest highlights, where CEO Hanna Sjöström shares insights into key milestones and the road ahead.
Insights from Redeye
At Neola Medical, transparency and long-term value creation are central to how we engage with our shareholders. To support investors with an independent perspective, Redeye provides ongoing equity research coverage of our company. Their analyses offer deeper insights into our technology, market opportunities, and strategic progress. Explore the latest report below.
Risks and Uncertainties
Neola Medical is exposed to a number of strategic, operational, and financial risks that could affect the company’s business and future development.
Learn more
Stock Information
Here you can find all relevant information about Neola Medical’s share, shareholders and capital data.
Learn more
Reports and Financial Calendar
View all our reports and follow our financial calendar to stay up to date.
Learn more
Investor Letters
We publish our investor letters about four times a year, providing a comprehensive update on Neola Medical’s progress and key milestones.
Learn more
Rights Issues
Rights issues are an important tool to finance our continued development and they offer shareholders the opportunity to participate directly in Neola Medical’s growth journey.
Learn more
Corporate Governance
At Neola Medical, strong corporate governance is the foundation for responsible growth and long-term value creation.
Learn more
Stay updated on our progress and milestones
Neola Medical is currently in clinical phase with Neola®, undergoing our first clinical study on preterm born babies in Sweden. As the company approaches commercial launch, the focus is on securing market authorization in the U.S., followed by Europe.